Cleveland, Ohio 44140

  • Bipolar Disorder


Inpatient Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Mania: This study recruits adult subjects who are diagnosed with Bipolar I Disorder and presently experiencing an episode of mania. Patients must be willing to spend initial 7 days in the hospital to observe response to medication. Patients must be refractory (intolerant or non-responsive) to treatment with lithium and valproate or carbamazepine. Patients receive study-related care at no cost. This study is sponsored by Eli Lilly and Company.


Inclusion Criteria: - The subject satisfied Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a primary diagnosis of Bipolar Disorder, most recently manic - The patient is willing to be hospitalized on an inpatient psychiatric unit for a minimum of seven (7) days. - Subject has been treated with lithium in the past. - Subject has been treated with divalproex or carbamazepine in the past. - Subject has been treated with Haldol or haloperidol in the past. Exclusion Criteria: - Subjects lacks the capacity to provide informed consent - Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators - Subject has been dependent on a drug (other than nicotine or caffeine) in the last three (3) months.



Primary Contact:

Principal Investigator
Joseph R Calabrese, MD
Case Western Reserve University / University Hospitals of Cleveland

Backup Contact:


Location Contact:

Cleveland, Ohio 44140
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.